

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2022/262796 A8

(43) International Publication Date
22 December 2022 (22.12.2022)

WIPO | PCT

(51) International Patent Classification:

C07D 487/04 (2006.01) C07C 1/00 (2006.01)
A61P 35/00 (2006.01) C07D 487/10 (2006.01)
A61K 31/53 (2006.01)

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(71) Applicant (for SC only): JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. [CN/CN]; 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN).

(21) International Application Number:

PCT/CN2022/099089

(22) International Filing Date:

16 June 2022 (16.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/100466
17 June 2021 (17.06.2021) CN
PCT/CN2022/091677
09 May 2022 (09.05.2022) CN

(72) Inventors: CAI, Wei; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). DAI, Xuedong; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). QUEROLLE, Olivier Alexis Georges; Janssen-Cilag, 1 Rue Camille Desmoulins, TSA 91003, 92787 Issy-les Moulineaux Cedex 9 (FR). THURING, Johannes Wilhelmus J.; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). NG, Alicia Tee Fuay; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). DARVILLE, Nicolas Freddy Jacques Bruno; Janssen

(54) Title: (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYL-HEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT FOR THE TREATMENT OF DISEASES SUCH AS CANCER




FIGURE 1

(57) Abstract: The present invention relates to (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl) amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt and solvates thereof. This compound may be useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compound, and use as menin/MLL protein/protein interaction inhibitor, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

[Continued on next page]

Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **GEERTMAN, Robert Michael**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **AHUJA, Dipali**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **LIU, Yingtao**; Johnson & Johnson (China) Investment Ltd., 2101, No.1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **PANDE, Vineet**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **CLEATOR, Edward**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **BEN HAIM, Cyril**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **SMOLDERS, Simon Jan C**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) **Agent: NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.**; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing 100013 (CN).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(81) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
 — *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
 — *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**

23 March 2023 (23.03.2023)

(15) **Information about Correction:**

see Notice of 23 March 2023 (23.03.2023)